Sign in
Taking people in South KoreaPhase 3

Tests two study drugs together in adults with high blood pressure and diabetes

Tests two study drugs combined in adults with high blood pressure and type 2 diabetes.

Key facts

Who runs it
Boryung Pharmaceutical Co., Ltd
Where
Seoul, South KoreaSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
Status
Recruiting
Phase
Phase 3
People taking part
276 people, planned
Started
21 May 2024
Expected to end
Dec 2026
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • BR1019A
  • BR1019B
  • BR1019C
  • BR1019A-1
  • BR1019B-1
  • BR1019C-1
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with both type 2 diabetes and essential hypertension (high blood pressure with no known other cause). They must be able to stop their current blood pressure and diabetes pills during the trial.

Age
19 years or older
Sex
All sexes can join.
Disease stage
Type 2 diabetes and essential hypertension. Severe or uncontrolled diabetes complications and secondary hypertension are not allowed.
Earlier treatment
People must agree to stop their current blood pressure and/or diabetes pills during the trial, and the investigator must judge this medically reasonable. Metformin is the exception.

Main reasons for not taking part

  • History or suspicion of secondary hypertension
  • Type 1 or secondary diabetes, diabetic ketoacidosis or lactic acidosis
  • Uncontrolled, severe diabetes complications
  • Diabetic coma or pre-coma
  • Diabetes with aliskiren use or moderate to severe kidney impairment

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Those with type 2 diabetes mellitus \& essential hypertension
  • Those who agree to discontinue existing antihypertensive and/or oral hypoglycemic drugs during the clinical trial
  • Those who are judged medically reasonable by investigator to be able to discontinue existing antihypertensive and/or oral hypoglycemic drugs(except for Metformin) during the clinical trial

Who cannot take part

  • Those who meet the following criteria; Those with a history of secondary hypertension or suspected secondary hypertension; (Including but not limited to; e.g., renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, primary hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma and polycystic kidney disease, etc.); Those with clinical significant orthostatic hypotension accompanied by symptoms; Those with diabetes mellitus taking renin inhibitors(Aliskiren) or moderate to severe renal impairment; Those with diabetic nephropathy taking ACE inhibitors; Those with type 1 diabetes mellitus, secondary diabetes mellitus, severe insulin-dependent diabetes, diabetic ketoacidosis or lactic acidosis; Those with uncontrolled, severe diabetic complications (Micro-vascular complications(e.g., nephropathy, retinopathy, neuropathy, etc.), Macro-vascular complications); Diabetic coma or pre-coma

Where in South Korea

Also in 1 other country, 1 site

  • Severance hospitalSeoul, South KoreaContact: Seok-min Kang, M.D., Ph.D.Taking people

About the trial

What the trial wants to find out

The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus

The 4 groups in the trial

  • BR1019A + BR1019B + BR1019C-1Treatment being tested

    Treatment: BR1019A, BR1019B, and BR1019C-1

  • BR1019A + BR1019B-1 + BR1019C-1Existing treatment, for comparison

    Treatment: BR1019A, BR1019B-1, and BR1019C-1

  • BR1019A-1 + BR1019B + BR1019C-1Existing treatment, for comparison

    Treatment: BR1019B, BR1019A-1, and BR1019C-1

  • BR1019A-1 + BR1019B + BR1019COther group

    Treatment: BR1019B, BR1019C, and BR1019A-1

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy in Patients With Essential Hypertension and Type 2 Diabetes Mellitus
Plain-language title
Tests two study drugs together in adults with high blood pressure and diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
16 October 2026